888504-27-6 (1,6-二氢-5-羟基-1-甲基-2-[1-甲基-1-[(苄氧基羰基)氨基]乙基]-6-氧代-4-嘧啶甲酸甲酯,Methyl 2-(2-(((benzyloxy)carbonyl)amino)propan-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylate)

CAS号:
888504-27-6
中文名称:
1,6-二氢-5-羟基-1-甲基-2-[1-甲基-1-[(苄氧基羰基)氨基]乙基]-6-氧代-4-嘧啶甲酸甲酯
英文名称:
Methyl 2-(2-(((benzyloxy)carbonyl)amino)propan-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylate
分子式:
C18H21N3O6
分子量:
375.38

1,6-二氢-5-羟基-1-甲基-2-[1-甲基-1-[(苄氧基羰基)氨基]乙基]-6-氧代-4-嘧啶甲酸甲酯(888504-27-6)名称与标识符

名称

中文别名:
1,6-二氢-5-羟基-1-甲基-2-[1-甲基-1-[(苄氧基羰基)氨基]乙基]-6-氧代-4-嘧啶甲酸甲酯;1,6-二氢-5-羟基-1-甲基-2-[1-[(苄氧基羰基)氨基]乙基-6-氧代-4-嘧啶甲酸甲酯;雷特格韦中间体C;雷特格韦中间体N-3;雷特格韦中间体2;1,6-二氢-5-羟基-1-甲基-2-[1-甲基-1-[(苄氧基羰基)氨基]乙基]-6-氧代-4-嘧啶甲酸甲酯(雷特格韦中间体) 1KG;1,6-二氢-5-羟基-1-甲基-2-[1-甲基-1-[(苄氧基羰基)氨基]乙基]-6-氧代-4-嘧啶甲酸甲酯(雷特格韦中间体);
英文别名:
Methyl 2-(2-(((benzyloxy)carbonyl)amino)propan-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylate;1,6-Dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[benzylcarbamoyl]amino]ethyl]-6-oxo-4-pyrimidinecarboxylic Acid Methyl Ester;1,6-DIHYDRO-5-HYDROXY-1-METHYL-2-[1-METHYL-1-[[(PHENYLMETHOXY)CARBONYL]AMINO]ETHYL]-6-OXO-4-PYRIMIDINECARBOXYLIC ACID M...;1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[(phenylmethoxy)carbonyl]amino]ethyl]-6-oxo-4-Pyrimidinecarboxylic acid methyl ester;1,6-Dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[benzylcarbamoyl]amino]ethyl]-6-oxo-4-pyrimidinecarboxylic Acid Methyl Es...;4-PYRIMIDINECARBOXYLIC ACID, 1,6-DIHYDRO-5-HYDROXY-1-METHYL-2-[1-METHYL-1-[[(PHENYLMETHOXY)CARBONYL]AMINO]ETHYL]-6-OXO-,;4-PYRIMIDINECARBOXYLIC ACID, 1,6-DIHYDRO-5-HYDROXY-1-METHYL-2-[1-METHYL-1-[[(PHENYLMETHOXY)CARBONYL]AMINO]ETHYL]-6-OXO-, METHYL ESTER;4-PYRIMIDINECARBOXYLIC ACID, 1,6-DIHYDRO-5-HYDROXY-1-METHYL-2-[1-METHYL-1-[[(PHENYLMETHOXY)CARBONYL]AMINO]ETHYL]-6-OXO-...;methyl 5-hydroxy-1-methyl-6-oxo-2-[2-(phenylmethoxycarbonylamino)propan-2-yl]pyrimidine-4-carboxylate;methyl 2-(2-{[(benzyloxy)carbonyl]amino}propan-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylate;4-Pyrimid;CID 54690598;Raltegravir Intermediate 2;InterMediate C of Raltegravir;1,6-Dihydro-5-hydroxy-1-Methyl-2-[1-Methyl-1-[[(phenylMethoxy)carbonyl]aMino]ethyl]-6-oxo-4-pyriMidineMethyl forMate;1,6-Dihydro-5-hydroxy-1-Methyl-2-[1-Methyl-1-[[benzylcarbaMoyl]a;Methyl 2-(2-(((benzyloxy)carbonyl)amino)propan-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidi;Methyl 1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[(phenylmethoxy)carbonyl]amino]ethyl]-6-oxo-4-pyrimidinecarboxylate (ACI);2-(1-Benzyloxycarbonylamino-1-methylethyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid Methyl Ester;Methyl2-(2-(((benzyloxy)carbonyl)amino)propan-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylate;1100750-74-0;SCHEMBL8266635;Methyl 2-(1-Cbz-NH-i-Pr)-5-OH-1-Me-6-oxo-1,6-dihydropyrimidine-4-carboxylate;69MXV4D5DS;SB57891;BCP13466;DB-059967;Methyl 2-[2-(benzyloxycarbonylamino)propan-2-yl]-5-hydroxy-1-methyl-6-oxo-1,6- dihydropyrimidine-4-carboxylate;CS-W005294;C18H21N3O6;MFCD10698809;Methyl 2-(2-(((benzyloxy)carbonyl)amino)propan-2-yl)-5-hydroxy-1-methyl-6-oxo-1 pound not6-dihydropyrimidine-4-carboxylate;888504-27-6;J-504034;Methyl 2-(2-(((benzyloxy)carbonyl)amino)propan-2-yl)-5-hydroxy-1-methyl-6-oxo-16-dihydropyrimidine-4-carboxylate;Methyl 1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[(phenylmethoxy)carbonyl]amino]ethyl]-6-oxo-4-pyrimidinecarboxylate;AC-25867;1,6-Dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[benzylcarbamoyl]amino]ethyl]-6-oxo-4-pyrimidinecarbox;1,6-dihydro-5-hydroxy-1-methyl-2-(1-methyl-1-(((phenylmethoxy)carbonyl)amino)ethyl)-6-oxo-4-pyrimidinecarboxylic acid methyl ester;DTXSID40715848;AKOS015899187;DS-1946;

标识符

MDL:
MFCD10698809
InChIKey:
SNDXNBICJATRDW-UHFFFAOYSA-N
Inchi:
1S/C18H21N3O6/c1-18(2,20-17(25)27-10-11-8-6-5-7-9-11)16-19-12(15(24)26-4)13(22)14(23)21(16)3/h5-9,22H,10H2,1-4H3,(H,20,25)
SMILES:
O=C(NC(C)(C)C1N(C)C(=O)C(O)=C(C(OC)=O)N=1)OCC1C=CC=CC=1

1,6-二氢-5-羟基-1-甲基-2-[1-甲基-1-[(苄氧基羰基)氨基]乙基]-6-氧代-4-嘧啶甲酸甲酯(888504-27-6)物化性质

实验特性

  • LogP : 1.82490
  • PSA : 119.75000
  • 折射率 : 1.58
  • 沸点 : No data available
  • 熔点 : 190-195°C
  • 闪点 : No data available
  • 溶解度 : DMSO
  • 颜色与性状 : 灰白色固体
  • 酸度系数(pKa) : 4.50±1.00(Predicted)
  • 密度 : 1.29

计算特性

  • 精确分子量 : 375.14300
  • 氢键供体数量 : 2
  • 氢键受体数量 : 7
  • 可旋转化学键数量 : 7
  • 同位素质量 : 375.143
  • 重原子数量 : 27
  • 复杂度 : 677
  • 同位素原子数量 : 0
  • 确定原子立构中心数量 : 0
  • 不确定原子立构中心数量 : 0
  • 确定化学键立构中心数量 : 0
  • 不确定化学键立构中心数量 : 0
  • 共价键单元数量 : 1
  • 疏水参数计算参考值(XlogP) : 1.8
  • 拓扑分子极性表面积 : 118

1,6-二氢-5-羟基-1-甲基-2-[1-甲基-1-[(苄氧基羰基)氨基]乙基]-6-氧代-4-嘧啶甲酸甲酯(888504-27-6)国际标准相关数据

EINECS:
922-554-0

1,6-二氢-5-羟基-1-甲基-2-[1-甲基-1-[(苄氧基羰基)氨基]乙基]-6-氧代-4-嘧啶甲酸甲酯(888504-27-6)海关数据

海关编码:
2933599090
海关数据:

中国海关编码:

2933599090

概述:

2933599090. 其他结构上有嘧啶环的化合物(包括其他结构上有哌嗪环的化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%

申报要素:

品名, 成分含量, 用途, 乌洛托品请注明外观, 6-己内酰胺请注明外观, 签约日期

Summary:

2933599090. other compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

1,6-二氢-5-羟基-1-甲基-2-[1-甲基-1-[(苄氧基羰基)氨基]乙基]-6-氧代-4-嘧啶甲酸甲酯(888504-27-6)推荐厂家 更多厂家(28)

1,6-二氢-5-羟基-1-甲基-2-[1-甲基-1-[(苄氧基羰基)氨基]乙基]-6-氧代-4-嘧啶甲酸甲酯(888504-27-6)合成路线

合成路线:1 步
反应条件:
参考文献:
(Chloromethyl)dimethylchlorosilane-KF: A Two-Step Solution to the Selectivity Problem in the Methylation of a Pyrimidone Intermediate en Route to Raltegravir
Stathakis, Christos I. ; Gkizis, Petros L.; Alexandraki, Elli S.; Trakossas, Sakellarios; Terzidis, Michael; et al, Organic Process Research & Development, 2017, 21(9), 1413-1418
合成路线:1 步
反应条件:
参考文献:
Improved synthesis of raltegravir
Guo, Diliang; Liu, Guannan; Li, Jian; Zhou, Yu; Xu, Jinyi; et al, Zhongguo Yaoke Daxue Xuebao, 2009, 40(4), 297-301
合成路线:1 步
参考文献:
A newfangled synthesis of integrase inhibitor drug substance raltegravir potassium
Rao, S. Venkat; Potluri, Vamsi Krishna; Potluri, Ramesh Babu, Asian Journal of Chemistry, 2019, 31(11), 2618-2622
合成路线:1 步
反应条件:
参考文献:
Development of a Second-Generation, Highly Efficient Manufacturing Route for the HIV Integrase Inhibitor Raltegravir Potassium
Humphrey, Guy R.; Pye, Philip J.; Zhong, Yong-Li; Angelaud, Remy; Askin, David; et al, Organic Process Research & Development, 2011, 15(1), 73-83
合成路线:1 步
反应条件:
参考文献:
Identification, Synthesis, and Strategy For Minimization of Potential Impurities Observed In Raltegravir Potassium Drug Substance
Patil, Gulabrao D.; Kshirsagar, Siddheshwar W.; Shinde, Shivnath B.; Patil, Pankaj S.; Deshpande, Mangesh S.; et al, Organic Process Research & Development, 2012, 16(8), 1422-1429

1,6-二氢-5-羟基-1-甲基-2-[1-甲基-1-[(苄氧基羰基)氨基]乙基]-6-氧代-4-嘧啶甲酸甲酯(888504-27-6)参考资料

Beilstein:
M195614
PubChem CID: